{"id":"hlx208","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, HLX208 blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on T-cell activation and proliferation, leading to enhanced anti-tumor immune responses.","oneSentence":"HLX208 is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:50:29.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT05902728","phase":"PHASE1","title":"Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2023-07-04","conditions":"NSCLC","enrollment":20},{"nctId":"NCT05841940","phase":"PHASE1","title":"Mass Balance Study of [14C]HLX208 in China Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2023-06-17","conditions":"Mass Balance Study in Healthy Subjects","enrollment":6},{"nctId":"NCT05102292","phase":"PHASE1, PHASE2","title":"The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2021-12-10","conditions":"Anaplastic Thyroid Cancer, ATC","enrollment":25},{"nctId":"NCT04984369","phase":"PHASE2","title":"The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2021-08-11","conditions":"CRC","enrollment":50},{"nctId":"NCT04965220","phase":"PHASE1","title":"HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-01-05","conditions":"Solid Tumor","enrollment":220},{"nctId":"NCT05127759","phase":"PHASE2","title":"The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-03-23","conditions":"Metastatic Colorectal Cancer, mCRC","enrollment":25},{"nctId":"NCT05092815","phase":"PHASE2","title":"The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2021-12-06","conditions":"Langerhans Cell Histiocytosis, Erdheim-Chester Disease, LCH","enrollment":25},{"nctId":"NCT05641493","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2023-02-28","conditions":"Non Small Cell Lung Cancer","enrollment":49},{"nctId":"NCT05528406","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-10-20","conditions":"Solid Tumor","enrollment":30},{"nctId":"NCT05114603","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-03-21","conditions":"Advanced Melanoma","enrollment":30},{"nctId":"NCT05092802","phase":"PHASE2","title":"The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2021-12-23","conditions":"Brain Tumor, Primary","enrollment":40},{"nctId":"NCT05065398","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2021-11-15","conditions":"NSCLC","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BRAF V600E inhibitor"],"phase":"phase_2","status":"active","brandName":"HLX208","genericName":"HLX208","companyName":"Shanghai Henlius Biotech","companyId":"shanghai-henlius-biotech","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HLX208 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}